Leadership
Management Team
Rick Wypych
President & Chief Executive Officer
Rick Wypych joined Cardiac Dimensions in 2003 and has served in a number of roles within the company. Rick has nearly 30 years of operational, financial, and strategic management experience in the financial, manufacturing and life sciences industries.
Prior to joining Cardiac Dimensions, Rick served as Director of Finance and Administration at Spinal Dynamics Corporation, an early-stage artificial intervertebral disc company. He was responsible for finance and accounting, human resources, and administration. During his tenure at Spinal Dynamics, Rick was instrumental in developing the initial revenues of the company, the financing of operations and the eventual sale of the company to Medtronic, Inc. Before joining Spinal Dynamics, he served as a Senior Audit Manager for KPMG LLP managing several financial audit engagements, mergers and acquisitions projects and SEC registrations.
Rick was also a member of the Board of Directors of Simplify Medical prior to its sale to NuVasive, Inc.
Rick holds a Bachelor of Arts degree in Business Administration from Albers School of Business at Seattle University and is a licensed Certified Public Accountant in the State of Washington.
William T. Abraham, MD
Chief Medical Officer
Dr. William T. Abraham joined Cardiac Dimensions in 2025 as Chief Medical Officer. He also serves as Professor of Medicine, Physiology, and Cell Biology at The Ohio State University Wexner Medical Center, where he previously directed the Division of Cardiovascular Medicine and served as Deputy Director of the Davis Heart and Lung Research Institute.
An internationally recognized leader in heart failure research, Dr. Abraham has led numerous pivotal clinical trials and authored more than 1,000 scientific publications, making him one of the most cited physician scientists in the field.
Robert Artman
Vice President, Therapy Development
Robert Artman joined Cardiac Dimensions in May of 2025 as the Vice President of Therapy Development. Robert brings with him more than two decades of experience in sales, market development and leadership experience in the cardiovascular medical device industry.
Prior to joining Cardiac Dimensions, Robert held a leadership role with P & F USA, Inc. helping build the US enterprise for P & F GmbH, an Austrian based structural heart company, and managing a large transcatheter Tricuspid Valve clinical trial. Robert also served in leadership roles with SentreHEART (acquired by Atricure) specializing in Left Atrial Appendage closure, and pivotal sales and market development roles with Abbott Vascular/Guidant. Robert has extensive experience bringing breakthrough technologies from an early clinical research stage through commercialization.
Robert received a Bachelor of Science degree in Allied Sciences from Neumann University and a Master of Business Administration from Haub School of Business at St. Joseph’s University.
Bob Calcote
Vice President, Operations & Compliance
Bob Calcote joined Cardiac Dimensions as Vice President of Operations in March 2014, bringing with him 40 years of manufacturing and engineering experience with more than 30 years in medical device operations, product development, regulatory, and quality system management.
Since 2000, Bob has held a number of senior management positions, serving as Vice President of Operations at RS Medical, Senior Vice President of Operations at ConforMIS, Vice President of Operations at Archus Orthopedics, and Vice President of Operations at Spinal Dynamics, where his management responsibilities included the manufacturing, product development, quality and regulatory activities. Earlier in his career, Bob was the Director of Manufacturing at C.R. Bard’s Impra Division, managing the ePTFE and polyester vascular graft manufacturing operations in the U.S. and France.
Bob received a Bachelor of Science degree in Electrical Engineering and a Master of Science degree in Biomedical Engineering from the University of Texas, Arlington.
Steven Goldberg, MD, FSCAI
Chief Clinical Officer
Steven Goldberg, MD, joined Cardiac Dimensions in 2006. In addition to serving as Chief Clinical Officer for Cardiac Dimensions, Dr. Goldberg is a practicing interventional cardiologist and the medical director for structural heart disease at Community Hospital of the Monterey Peninsula in Monterey, Ca.
Previously Dr. Goldberg served as an Associate Professor of Medicine and Director of the Cardiac Catheterization Lab at University of Washington Medical Center.
Dr. Goldberg received a medical degree and bachelors of arts from the University of Kansas and completed Fellowships in Internal Medicine and Cardiology at Cedars-Sinai Medical Center and the University of California, Irvine respectively.
Hank Hauser
Vice President, Clinical
Joining Cardiac Dimensions in 2024 after more than 30 years in clinical operations, Hank Hauser collaborates with leading physicians, scientists and research staff to deliver best-in-class clinical trial design and execution. A life-sciences veteran and clinical affairs expert, Hank has led investigations globally, spanning more than 15 countries.
Serving as clinical lead across multiple companies, Hank initiated and completed numerous multi-center/multi-country First-in-Human, pivotal, and post-market studies resulting in acquisitions by Boston Scientific and Merz Aesthetics. Together with his team Hank provides strategic direction and clinical oversight to help reach the company’s global business goals.
Hank received a Bachelor of Science degree in Radiology with a minor in business administration from the University of Oklahoma.
Carmelo Mastrandrea
Vice President, Sales
Carmelo Mastrandrea joined Cardiac Dimensions in 2019, bringing with him almost 20 years of experience in sales, 14 of which are in the medical device industry, including more than 10 years in cardiovascular medical devices.
Prior to joining Cardiac Dimensions, Carmelo was at REVA Medical as Vice President of Sales, Europe. Carmelo also served as General Manager for Biosensors Europe SA’s business in the D-A-CH region (Germany, Austria, and Switzerland) and held management positions with Biotronik Schweiz AG and Guidant AG.
Carmelo received Swiss Federal diplomas in Machine Engineering from Mitecha Engineering School in Aarau and Business from KV Business School in Basel.
Board Members
Rick Wypych
President & Chief Executive Officer
Rick Wypych joined Cardiac Dimensions in 2003 and has served in a number of roles within the company. Rick has nearly 30 years of operational, financial, and strategic management experience in the financial, manufacturing and life sciences industries.
Prior to joining Cardiac Dimensions, Rick served as Director of Finance and Administration at Spinal Dynamics Corporation, an early-stage artificial intervertebral disc company. He was responsible for finance and accounting, human resources, and administration. During his tenure at Spinal Dynamics, Rick was instrumental in developing the initial revenues of the company, the financing of operations and the eventual sale of the company to Medtronic, Inc. Before joining Spinal Dynamics, he served as a Senior Audit Manager for KPMG LLP managing several financial audit engagements, mergers and acquisitions projects and SEC registrations.
Rick was also a member of the Board of Directors of Simplify Medical prior to its sale to NuVasive, Inc.
Rick holds a Bachelor of Arts degree in Business Administration from Albers School of Business at Seattle University and is a licensed Certified Public Accountant in the State of Washington.
Mark Carnegie
M. H. Carnegie & Co.
Mark Carnegie is the Founder and Managing Director of M. H. Carnegie & Co. Mark has more than 30 years of experience as an entrepreneur, investor and corporate adviser in New York, London and Sydney.
He co-founded leading Australian boutique corporate advisory, venture capital and private equity firm Carnegie, Wylie & Co with John Wylie in 2000. In August 2007, Carnegie Wylie was acquired by leading Wall Street bank, Lazard Inc.
Prior to Carnegie Wylie, Mark trained on Wall Street with James D. Wolfensohn and worked with Lloyd Williams at Hudson Conway in London. Mark was the Australian and Asian representative of Hellman & Friedman for much of the 1990s. In addition to being involved in a range of diverse Australian and Asian investments, Mark has been a participant in groups that have acquired major stakes in the Courage Pub Estate, John Fairfax Holdings, Hoyts Cinemas, Formula One Holdings, SCTV, Macquarie Radio Network and Lonely Planet Publications and London Sumatra Plantations. As a corporate adviser, Mark has advised Qantas and Coles Myer on general strategic matters, Westfield on its $22 billion merger and Qantas on its JetStar Asia start-up in Singapore.
Mark holds a bachelor of arts degree from Oxford University and a BSc (Hons) from Melbourne University. He is a former Treasurer of the Oxford Union.
Daniel Hetu
Lumira Ventures
With 20 years of investment banking, corporate and business development, and licensing experience, Daniel has been involved with life science companies at all stages of development in North America and overseas.
Before joining Lumira Ventures in 2005, Daniel located in Montréal, spent 10 years at Shire Pharmaceuticals and at Biochem Pharma prior to its acquisition by Shire as Vice President, Business Development North America (Shire), and Vice President, Corporate Development (Biochem Pharma). During that period, he was involved with the in-licensing of a wide range of products and technologies as well as several financing and M&A transactions in the therapeutics, vaccine and diagnostics sectors. At Biochem, Daniel served on the Company’s portfolio committee and the steering committee of strategic research collaborations.
Prior to joining Biochem Pharma, Daniel was an investment banker at a major Canadian investment bank where he was involved in M&A and financing transactions across various industrial sectors.
Daniel holds an MD from Université de Sherbrooke, Québec, and an MBA from École des Hautes Études Commerciales (Montréal, Québec).
Matt McNamara
Horizon 3 Healthcare
Mr. McNamara joined the Board in December 2022. He has over 30 years’ experience in the healthcare and medical sciences sector.
In 2003, he founded BioBridge Australia, a biotechnology commercialisation advisory company and advised a number of public biotechnology / investment companies. He is presently a director of Adherium Ltd (ASX:ADR), SciCapital Pty Ltd and Grey Innovation Group Pty Ltd. He has held previous directorship in, Avita Medical Ltd, Bioxyne Ltd, and Rex Bionics Pty Ltd.
Mr. McNamara has also served as CIO of BioScience Manager Pty Ltd, was CEO of SciCapital Pty Ltd, a Life Sciences Venture Capital fund, SVP Business Development for eBioinformatics Inc, General Manager of Vistakon Pty Ltd (a Johnson & Johnson Medical franchise), and held numerous management positions in Australia with Merck & Co.
Mr. McNamara has a BSc (Hons) in Molecular Biology and is also a holder of an MBA.
Trevor Moody
Independent Board Member & Board Chair
Mr. Moody served as Medical Device Partner at M.H. Carnegie & Co. from 2013 to 2022. He was previously a General Partner at Frazier Healthcare Ventures, a large U.S. based private equity firm.
Mr. Moody brings significant experience with over 25 years in the development, commercialization and funding of innovative, growth-oriented medical technologies.
Steven Plachtyna
Ally Bridge Group
Steven Plachtyna joined the Cardiac Dimensions Board in March 2025. Steven is a Vice President at Ally Bridge Group. He joined the firm in 2020 contributing across both the public equity and private equity strategies.
Before joining Ally Bridge Group, Steven was a Senior Research Associate at Citi and BMO Capital Markets covering Medical Technologies. Steven began his career at Covidien in Research and Development and holds a BS in Biomedical Engineering from the University of Connecticut, as well as both a M.Eng. in Biomedical Engineering and MBA from Cornell University.
Bob White
Independent Board Member
Bob White has nearly 30 years of experience leading early-stage companies and Fortune 500 business units within the medical technology sector. Bob most recently served as President and Chief Executive Officer of Entellus Medical, Inc., which was acquired by Stryker in February 2018.
Bob made a measurable impact at Entellus as a strong and passionate leader within the ear, nose and throat surgery space, driving his business to successfully treat more than 250,000 patients suffering from chronic sinusitis, Eustachian tube dysfunction and airway obstruction. In 2018, Bob was recognized as a finalist in the Ernst & Young Entrepreneur of the Year and the YPO Global Innovation Award. Bob currently serves as a Director on the Board of portfolio companies Cardiva Medical (acquired by Haemonetics) and TissueTech.
Previously, Bob was the President and Chief Executive Officer of TYRX, Inc., which specialized in commercializing innovative, implantable combination drug and device products focused on infection control until TYRX was sold to Medtronic in 2014. Along the way, TYRX was named to the Fierce Medical Devices “Fierce 15,” designating it as one of the leading medical device and diagnostic companies.
Prior to joining TYRX, Bob held several executive positions with Medtronic, including serving as President of Physio Control, Vice President of Commercial Operations of the Cardiac Rhythm Disease Management business, and President of Kyphon following its $3.9 billion acquisition of the spinal treatment business. Earlier in his career, Bob held leadership positions in business development, international sales and marketing, operations, and general management with Instromedix/Life Watch, Eli Lilly, IVAC/Alaris Medical, and General Electric.
Bob currently also serves as a Director on the Board of Atricure Inc. (NASDAQ: ATRC). During the past year, two other companies that Bob actively served as a Director for were acquired for significant premiums, including Novadaq Technologies and privately held Hyperbranch Medical Technology.
Bob holds a bachelors of science degree in Aerospace Engineering from the University of Missouri-Rolla and a master of business administration degree from Cornell University.
